linjc16/ctgov huggingface dataset:
the Hypoalgesic Effect of Spinal Manual Therapy

Study Overview
=================
Brief Summary
-----------------
To study the immediate effect of spinal manual therapy on pain perception in normal subjects

Detailed Description
-----------------
Is this effect only local or is it also noticed away from the stimulated area? How long does it last? Is there a dose/response phenomenon?

Official Title
-----------------
the Hypoalgesic Effect of Spinal Manual Therapy on an Healthy Population: a Randomized Clinical Trial

Conditions
-----------------
Back Pain

Intervention / Treatment
-----------------
* Device: spinal manual therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy Students who volunteer from Murdoch University - Exclusion Criteria: contraindication to spinal manual therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sham Comparator: sham spinal manual therapy<br>activator set to zero | Device: spinal manual therapy<br>* spinal manipulation either manual or instrumental (activator)<br>* Other names: activator;|
| Experimental: percussive spinal manual therapy<br>activator set to the maximum force | Device: spinal manual therapy<br>* spinal manipulation either manual or instrumental (activator)<br>* Other names: activator;|
| Experimental: Firm thoracic spinal manual therapy<br>Firm thoracic manipulation | Device: spinal manual therapy<br>* spinal manipulation either manual or instrumental (activator)<br>* Other names: activator;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the Pressure pain threshold in KPa/Cm2 will be measure with an Algometer (SOMEDIC) |  | the pressure pain threshold will be measure immediately after intervention and every 15 minutes during 1 hour |
Prenatal Breastfeeding Education to Reduce Nipple Pain

Study Overview
=================
Brief Summary
-----------------
This study is a randomized controlled trial to evaluate the effectiveness of different approaches to prenatal teaching of infant latch.

Official Title
-----------------
Prenatal Breastfeeding Education to Reduce Nipple Pain

Conditions
-----------------
Nipple Pain During Lactation

Intervention / Treatment
-----------------
* Behavioral: Education


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnant women who intend to breastfeed their infants Single infant Resides in catchment area Has phone Speaks English

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Education on Infant-led latching<br> | Behavioral: Education<br>* Education on Infant-led latching<br>|
| No Intervention: Standard education<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nipple pain day 3 postpartum |  | Day 3 postpartum | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Breastfeeding status day 30 postpartum |  | Day 30 postpartum | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nipple pain during lactation
Remove LPS Registry

Study Overview
=================
Brief Summary
-----------------
This registry will collect and validate regulatory-grade real-world data (RWD) on the usage of the LPS-Adsorber and the outcomes from using the LPS-Adsorber in various patient populations (various sub-registries) that also have suspected endotoxemia. This data can be then used in real-world evidence (RWE) generation. It will also create reusable infrastructure to allow creation or affiliation with many additional RWD/RWE efforts both prospective and retrospective in nature.

Official Title
-----------------
Post Market Clinical Follow up (PMCF) Medical Device (MD) Registry of the Alteco® LPS Adsorber to Remove Lipopolysaccharide (LPS) in Patients With Suspected Endotoxemia, With Severe Symptom(s)/Complication(s) and Their Stabilization Outcomes: REMOVE LPS Registry

Conditions
-----------------
Suspected or Diagnosed Endotoxemia Casued by Gram-negative Bacteria

Intervention / Treatment
-----------------
* Device: LPS Adsorber


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Weight > 30 kilos Specific sub-registry criteria are possible. Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Retrospective<br>Patients not treated with LPS Adsorber | |
| Prospective<br>Patients treated with LPS Adsorber | Device: LPS Adsorber<br>* LPS Adsorber, binding endotoxin caused by suspected or verified gram-negative bacteria.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary endpoint will be the time needed to achieve patient stabilization from the time of treatment. |  | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Secondary Outcomes will be to document the change in a patient's symptoms of infection over time. |  | 30 days | 
| Rate of complaints and incidents related to the medical device during the whole registry. |  | 30 days |
Correlation of Endoscopic Findings and Symptoms in Patients Undergoing the First Upper Gastrointestinal Endoscopy

Study Overview
=================
Brief Summary
-----------------
Endoscopy is the best means of finding early stage of upper gastrointestinal diseases, especially early cancer and benign ulcers. Currently, most people still undergo upper gastrointestinal endoscopy due to discomfort, rather than a regular physical examination at a certain age. This study prospectively investigated the reason for undergoing the first upper gastrointestinal endoscopy in patients and found the correlation of endoscopic findings and symptoms.

Official Title
-----------------
Correlation of Endoscopic Findings and Symptoms in Patients Undergoing the First Upper Gastrointestinal Endoscopy

Conditions
-----------------
Symptoms and Signs, Malignancy, Ulcer Peptic

Intervention / Treatment
-----------------
* Procedure: endoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing the first upper gastrointestinal endoscopy. Exclusion Criteria: The patients had previously performed endoscopy and any esophageal, gastric or duodenal surgery. The patients couldn't complete the questionnaire survey under the guidance of physicians at the appointment of the upper gastrointestinal endoscopy.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: endoscopy|All endoscopy was performed by qualified gastroenterologists or endoscopic physicians in Renji hospital,Shanghai Jiaotong University School of Medicine.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of endoscopic findings and symptoms | survey | Within two weeks after receiving the survey | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The proportion of various symptoms in patients undergoing the first upper gastrointestinal endoscopy |  | Within two weeks after receiving the survey | 
| The proportion of different upper gastrointestinal diseases | Diagnosis of upper gastrointestinal disease combined with endoscopic findings and pathological diagnosis. | Within two weeks after receiving the survey | 
| The infection rate of Helicobacter Pylori | H. pylori infection was determined by any two of positive outcome of the breath test, rapid urease test and histology. | Within two weeks after receiving the survey |
Obstructive Sleep Apnea (OSA) Anesthesia and Positive Airway Pressure

Study Overview
=================
Brief Summary
-----------------
To determine if autotitrating positive airway pressure (APAP) naïve patients with OSA can successfully use APAP following general anesthesia.

Official Title
-----------------
Obstructive Sleep Apnea (OSA) Anesthesia and Positive Airway Pressure

Conditions
-----------------
Obstructive Sleep Apnea

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Obstructive Sleep Apna Exclusion Criteria: non conformers

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sleep, apnea
Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan

Study Overview
=================
Brief Summary
-----------------
This is an open-label, multi-center, dose-escalation and safety expansion, Phase I study to evaluate the safety, tolerability, and pharmacokinectics and to investigate biomarker changes of AZD7762 administered as a single intravenous unit and in combination with irinotecan. The study is sponsored by AstraZeneca.

Official Title
-----------------
A Phase I Open-label, Multi-center, Dose-escalation and Safety Expansion Study to Assess Safety, Tolerability, and Pharmacokinectics of AZD7762 Administered as a Single Intravenous Agent and in Combination With Weekly Standard Dose of Irinotecan in Patients With Advanced Solid Malignancies.

Conditions
-----------------
Advanced Solid Tumors, Cancer, Advanced Solid Malignancies

Intervention / Treatment
-----------------
* Drug: AZD7762
* Drug: Irinotecan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Advanced solid tumors for which standard treatment doesn't exist or is no longer effective. Must be suitable for treatment with irinotecan Relatively good overall health other than your cancer Exclusion Criteria: Poor bone marrow function (not producing enough blood cells) Serious heart conditions Poor liver or kidney function Any prior anthracycline treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>AZD7762 monotherapy followed by AZD7762 + irinotecan | Drug: AZD7762<br>* intravenous infusion<br>Drug: Irinotecan<br>* intravenous injection<br>* Other names: irinotecan hydrochloride;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary objective of this study is to assess the safety and tolerability of AZD7762 alone and in combination with Irinotecan |  | assessed after each course of treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine the single-dose (after the first single-agent dose) and combination-dose (afer the 2nd combination dose) pharmacokinetics (PK) of AZD7762. |  | assessed after each course of treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Phase I, solid tumors, solid malignancies, cancer Eligibility
Evaluation of the Efficacy of Intralesional Injection of Combined Digoxin and Furosemide Versus 5 - Fluorouracil in Treatment of Plantar Warts

Study Overview
=================
Brief Summary
-----------------
Warts are common skin infections caused by human papillomavirus (HPV), which can cause a variety of skin presentations according to its type, site and the immune status .Nongenital warts may be presented as common, plane, plantar, filiform, or mucosal warts .Most people are affected by cutaneous warts, either plantar warts or common warts .prevalence of skin warts is between 3% and 13% and plantar warts are about 30% of skin warts in western world .Majority of cases occur in adolescent and young adults

Official Title
-----------------
Evaluation of the Efficacy of Intralesional Injection of Combined Digoxin and Furosemide Versus 5 - Fluorouracil in Treatment of Plantar Warts

Conditions
-----------------
Plantar Wart

Intervention / Treatment
-----------------
* Drug: combined digoxin and furosemide
* Drug: 5 fluorouracil


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age:>18 years . Sex: both males and females will be included. Confirmed diagnosis by clinical and dermoscopic examination of plantar warts will be made Exclusion Criteria: Patients with history or evidenced hypersensitivity to any component used in this study. Pregnancy & lactating. Patients who receive immune suppressive therapy. Patients who receive any wart treatment during the last 2 months before enrollment in the study. Patients with systemic illness especially cardiac patients. Patients who refused participation in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: group A<br>patients will receive intralesional combined digoxin and furosemide , one session every 2 weeks for maximum 6 sessions | Drug: combined digoxin and furosemide<br>* one session every 2 weeks for maximum 6 sessions<br>|
| Active Comparator: group B<br>patients will receive intralesional 5 fluorouracil mixed with 1ml of 2% lignocaine and epinephrine one session every 2 weeks for maximum 6 sessions . | Drug: 5 fluorouracil<br>* 5 fluorouracil mixed with1ml of 2% lignocaine and epinephrine one session every 2 weeks for maximum 6 sessions .<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the change in size of plantar wart | measurement the change in size of plantar wart | 3 month | 
| the change in number of plantar warts | measurement the change in number of plantar warts | 3 month |
Prospective, Multicenter Study of the Efficacy and Tolerance of Tacrolimus on Refractory Nephrotic Syndrome (RNS)

Study Overview
=================
Brief Summary
-----------------
Exploring the efficacy and safety of Tacrolimus on refractory nephrotic syndrome ; Acquiring the experience of Tacrolimus on the treatment of refractory nephrotic syndrome in Chinese patients.

Conditions
-----------------
Kidney Diseases, Nephrotic Syndrome, Tacrolimus

Intervention / Treatment
-----------------
* Drug: tacrolimus (FK506)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects of either sex, 14-65 years of age; Diagnosis of Nephrotic syndrome with hypoalbuminemia (<3.0g/dl) and heavy proteinuria (> 3.5g/24hr); Provision of written informed consent by subject or guardian; Refractory nephrotic syndrome: Steroid resistant: Persistence of proteinuria despite prednisone therapy 1mg/kg/d for 16 weeks; Steroid dependent: NS recurs when steroid dosage decease.Twice within 6 months, and 3 times within 1 year. Exclusion Criteria: Inability or unwillingness to provide written informed consent ; Known hypersensitivity or contraindication to tacrolimus, cyclophosphamide, azathioprine, corticosteroids; Usage of immunosuppression therapy (MMF, CTX, CysA, MTX ect) for more than 1 week within 1 month prior to first randomization; Pregnancy, nursing or use of a non-reliable method of contraception; Continuous dialysis starting more than 2 weeks before randomization into the induction phase and/or continuous dialysis with an anticipated duration of more than 8 weeks; Previous kidney transplant or planted transplant; Scr > 4mg/dl (353umol/L); Active hepatitis, with liver dysfunction; Diagnosed DM; Participation in another clinic trial and/or receipt of investigational drugs within 4 weeks prior to screening .

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: tacrolimus(fk506) treatment<br>tacrolimus(fk506) treatment | Drug: tacrolimus (FK506)<br>* Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Remission rate |  | 2006-2008 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Renal function, proteinuria, relapse |  | 2006-2008 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Refractory Nephrotic syndrome, Tacrolimus
Circulating Tumor Cells (CTC) in Cancer

Study Overview
=================
Brief Summary
-----------------
This observational study with circulating tumor cells (CTC) count, isolation and analysis at several time points during disease progression is to investigate the role and biology of CTCs and clusters of CTCs in different cancer types. It also evaluates the role of CTCs as biomarkers, and aims at the identification of key signaling networks that are active in CTCs.

Official Title
-----------------
Circulating Tumor Cells (CTC) in Cancer

Conditions
-----------------
Cancer

Intervention / Treatment
-----------------
* Other: Blood samples
* Other: Samples from tumor draining vessels


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult cancer patients All patients with histology-based proved diagnosis of cancer, all stages and subtypes can be included. Precancerous lesions cannot be included. All patients with the diagnosis of a solid tumor including adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma, sarcoma Written pathology report must be available. Written informed consent. Exclusion Criteria: No written informed consent. No proved diagnosis of malignancy by pathology report. Patients with the diagnosis of blood cancer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Blood samples|Blood samples (3 ethylenediaminetetraacetic acid (EDTA) tubes with a volume of 7.5 ml blood each) will be processed for CTC isolation and characterization, ranging from molecular analysis to culture and drug screen.|
|Other: Samples from tumor draining vessels|In case of tumor resection, 3 EDTA tubes (5 ml) will be withdrawn from the tumor draining vessels for CTC isolation and characterization, ranging from molecular analysis to culture and drug screen.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival (OS) in heterogeneous cancer population | overall survival (OS) in heterogeneous cancer population | Screening (Visit 1) until the date of death (assessed up to 240 months) | 
| Change in total number of isolated CTCs | Change in total number of isolated CTCs | Through study completion, an average of 20 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression free survival (PFS) | progression free survival (PFS) in the different cancer cohorts with different treatment regimes | Through study completion, an average of 20 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
circulating tumor cells (CTCs), CTC clusters, Molecular analysis of CTCs, CTC culture, overall survival (OS), progression free survival (PFS)